Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RepHresh is a prominent women's healthcare brand specializing in vaginal microbiome maintenance and pH balance, currently owned and marketed by Church & Dwight. Its flagship product, RepHresh Pro-B, is a clinically evaluated daily probiotic supplement containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, designed to promote healthy vaginal flora. The brand portfolio also includes the RepHresh Vaginal Gel, an over-the-counter treatment formulated to stabilize vaginal pH and alleviate related discomforts for up to three days. Originally developed through extensive academic research into the protective role of lactobacilli, the brand was acquired by Church & Dwight in 2011 for $215 million. RepHresh remains a leading name in the feminine care category, providing evidence-based solutions for managing vaginal dysbiosis and supporting overall feminine wellness.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RepHresh Pro-B.